Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ZoetisCHIX:ZOED 68 Days Payable is 64.90 as of Jun. 2026, which is 9% above its 10-year median of 59.64. GuruFocus rates CHIX:ZOED with a GF Score™ of 68/100 and a GF Value™ of €158.19 (Significantly Undervalued). Among 925 Drug Manufacturers companies, Zoetis ranks worse than 64.65% on this metric.
Zoetis's average Accounts Payable for the
three
months ended in Jun. 2026 was €415 Mil. Zoetis's Cost of Goods Sold for the
three
months ended in Jun. 2026 was €584 Mil.
Hence, Zoetis's Days Payable for the
three
months ended in Jun. 2026 was 64.90.
The historical rank and industry rank for Zoetis's Days Payable or its related term are showing as below:
CHIX:ZOEd'
s Days Payable Range Over the Past 10 Years
Min: 54.08 Med: 59.64 Max: 70.77
Current: 63.7
During the past 13 years, Zoetis's highest Days Payable was 70.77. The lowest was 54.08. And the median was 59.64.
CHIX:ZOEd's Days Payable is ranked worse than 64.65% of 925
companies
in the Drug Manufacturers industry
Industry Median: 89.27
vs CHIX:ZOEd: 63.70
Zoetis's Days Payable
declined
from Jun. 2025 (65.70) to Jun. 2026 (64.90).
It may suggest that Zoetisaccelerated paying its suppliers.
The historical data trend for Zoetis's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:ZOED vs UTHR, VTRS, NBIX: Days Payable Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Zoetis's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zoetis Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Zoetis's Days Payable distribution charts can be found below:
* The bar in red indicates where Zoetis's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Zoetis's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zoetis (CHIX:ZOED) has a Days Payable of 64.90 as of Jun. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Zoetis and its competitors. This is near median its historical median of 59.64. Over the past decade, Zoetis' Days Payable has ranged from 54.08 to 70.77. According to the industry distribution chart, Zoetis ranks #598 out of 925 companies in the Drug Manufacturers industry, placing it in the top 64.6%.
Is Zoetis' Days Payable too high?
Zoetis' current Days Payable of 64.90 is near median its 10-year median of 59.64. Over the past 10 years, this metric has ranged from a low of 54.08 to a high of 70.77. The Drug Manufacturers industry median Days Payable is 89.27. Zoetis' value of 64.90 is 27.3% below this industry median. Based on the distribution chart, Zoetis ranks #598 out of 925 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Zoetis has a GF Score™ of 68/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Zoetis' Days Payable compare to UTHR and VTRS?
According to the Drug Manufacturers industry distribution chart, Zoetis ranks #598 out of 925 companies for Days Payable. This places Zoetis in the lower half of its industry. The industry median Days Payable is 89.27. Zoetis' value of 64.90 is 27.3% below this benchmark. Historically, Zoetis' own Days Payable has ranged from 54.08 to 70.77 over the past decade. While the company's 10-year median is 59.64 vs. the industry median of 89.27, Zoetis has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 89.27, based on 925 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zoetis's current Days Payable of 64.90 is 27.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Zoetis and its competitors. For the Drug Manufacturers industry, the median Days Payable is 89.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zoetis's current Days Payable is 64.90, which is near median its own 10-year median of 59.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zoetis stock overvalued right now?
Based on GuruFocus' analysis, Zoetis (CHIX:ZOED) is currently considered Significantly Undervalued. The stock's GF Value™ is €158.19, compared to a current price of €66.42 — trading 58% below its estimated fair value. The current Days Payable is 64.90, which is near median its 10-year median of 59.64 and 27.3% below the Drug Manufacturers industry median of 89.27. Zoetis' overall GF Score™ is 68/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Zoetis (CHIX:ZOED), the current Days Payable is 64.90 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zoetis (CHIX:ZOED) Overvalued in 2026?
Based on GuruFocus' analysis, Zoetis stock appears to be undervalued.
The current stock price of €66.42 is trading 58% below its estimated GF Value™ of €158.19.
GuruFocus considers Zoetis to be Significantly Undervalued.
Key valuation signals for CHIX:ZOED:
Days Payable: 64.90 (near median its 10-year median of 59.64)
GF Value™: €158.19 vs. price of €66.42 (58% below fair value)
Industry Position: 27.3% below the Drug Manufacturers median (#598 of 925)
No single metric tells the full story. See the CHIX:ZOED stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 65% from companion animal (dogs, horses, cats) products. Its US business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
68GF Score
Get the complete analysis for CHIX:ZOED
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:ZOED has been successfully added to your 
